Last reviewed · How we verify

Autologous serum — Competitive Intelligence Brief

Autologous serum (Autologous serum) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous biological product. Area: Ophthalmology.

marketed Autologous biological product Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Autologous serum (Autologous serum) — Anita Syla Lokaj. Autologous serum is a patient's own blood serum used topically to provide growth factors and immunomodulatory components that promote tissue healing and reduce inflammation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Autologous serum TARGET Autologous serum Anita Syla Lokaj marketed Autologous biological product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous biological product class)

  1. Anita Syla Lokaj · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Autologous serum — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-serum. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: